March 28, 2019
Jamie Blundell, President & COO is pleased to provide the following update on CB2 Insights, one of CGOC’s public holdings:
CB2 Insights (“CB2”), one of CGOC’s private portfolio holdings that recently went public, recently announced the signing of an agreement with Premier Health Group (“Premier Health”), to integrate CB2’s Clinical Decision Support (“CDS”) tool to assist physicians and healthcare practitioners in their ability to qualify and prescribe medical cannabis.
The agreement will give more than 4,600 physicians and healthcare practitioners using Premier Health’s Juno EMR platform access to the industry’s only medical cannabis-specific CDS tool. CB2’s CDS tool is designed to help incorporate medical cannabis into their patient’s treatment plans. This first-of-its-kind integration in the medical cannabis sector will allow physicians and healthcare practitioners to overcome many of the barriers they face from a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy, all on a patient-specific basis using clinically-validated data.
As part of the agreement, CB2 will provide the development and continuous maintenance and support of the CDS tool and all related technologies. Premier Health will support by providing access to their software and will engage its network of physicians and other healthcare professionals to assist in the adoption of the CDS tool.
For further information please contact Cannabis Growth Opportunity Corporation:
|Website: www.cgocorp.com||Investor Relations Email: email@example.com|
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.
For more information please visit www.cb2insights.com